439 related articles for article (PubMed ID: 10770174)
21. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
[TBL] [Abstract][Full Text] [Related]
22. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial.
Midyett LK; Rogol AD; Van Meter QL; Frane J; Bright GM;
J Clin Endocrinol Metab; 2010 Feb; 95(2):611-9. PubMed ID: 19880790
[TBL] [Abstract][Full Text] [Related]
23. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency.
Boot AM; Engels MA; Boerma GJ; Krenning EP; De Muinck Keizer-Schrama SM
J Clin Endocrinol Metab; 1997 Aug; 82(8):2423-8. PubMed ID: 9253311
[TBL] [Abstract][Full Text] [Related]
24. [Biological and clinical analyses of the mechanism of growth retardation and the effect of recombinant human insulin-like growth factor-1 (rhIGF-1) treatment on glucose metabolism and growth in leprechaunism with severe insulin resistant diabetes].
Kato M
Hokkaido Igaku Zasshi; 1998 Nov; 73(6):613-25. PubMed ID: 10036618
[TBL] [Abstract][Full Text] [Related]
25. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth.
Carroll PV; Drake WM; Maher KT; Metcalfe K; Shaw NJ; Dunger DB; Cheetham TD; Camacho-Hübner C; Savage MO; Monson JP
J Clin Endocrinol Metab; 2004 Aug; 89(8):3890-5. PubMed ID: 15292323
[TBL] [Abstract][Full Text] [Related]
26. rhIGF-1 Treatment Increases Bone Mineral Density and Trabecular Bone Structure in Children with PAPP-A2 Deficiency.
Hawkins-Carranza FG; Muñoz-Calvo MT; Martos-Moreno GÁ; Allo-Miguel G; Del Río L; Pozo J; Chowen JA; Pérez-Jurado LA; Argente J
Horm Res Paediatr; 2018; 89(3):200-204. PubMed ID: 29455208
[TBL] [Abstract][Full Text] [Related]
27. Effects of recombinant human insulin-like growth factor (IGF)-I and estrogen administration on IGF-I, IGF binding protein (IGFBP)-2, and IGFBP-3 in anorexia nervosa: a randomized-controlled study.
Grinspoon S; Miller K; Herzog D; Clemmons D; Klibanski A
J Clin Endocrinol Metab; 2003 Mar; 88(3):1142-9. PubMed ID: 12629097
[TBL] [Abstract][Full Text] [Related]
28. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
29. Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans.
Lieberman SA; Bukar J; Chen SA; Celniker AC; Compton PG; Cook J; Albu J; Perlman AJ; Hoffman AR
J Clin Endocrinol Metab; 1992 Jul; 75(1):30-6. PubMed ID: 1377706
[TBL] [Abstract][Full Text] [Related]
30. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
[TBL] [Abstract][Full Text] [Related]
31. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL
J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
[TBL] [Abstract][Full Text] [Related]
32. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype.
Azcona C; Preece MA; Rose SJ; Fraser N; Rappaport R; Ranke MB; Savage MO
Clin Endocrinol (Oxf); 1999 Dec; 51(6):787-92. PubMed ID: 10619985
[TBL] [Abstract][Full Text] [Related]
33. Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency.
Bachrach LK; Marcus R; Ott SM; Rosenbloom AL; Vasconez O; Martinez V; Martinez AL; Rosenfeld RG; Guevara-Aguirre J
J Bone Miner Res; 1998 Mar; 13(3):415-21. PubMed ID: 9525342
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
[TBL] [Abstract][Full Text] [Related]
35. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
[TBL] [Abstract][Full Text] [Related]
36. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa.
Misra M; Miller KK; Cord J; Prabhakaran R; Herzog DB; Goldstein M; Katzman DK; Klibanski A
J Clin Endocrinol Metab; 2007 Jun; 92(6):2046-52. PubMed ID: 17356044
[TBL] [Abstract][Full Text] [Related]
37. Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects.
Hayes VY; Urban RJ; Jiang J; Marcell TJ; Helgeson K; Mauras N
J Clin Endocrinol Metab; 2001 May; 86(5):2211-9. PubMed ID: 11344229
[TBL] [Abstract][Full Text] [Related]
38. The effects of anorexia nervosa on bone metabolism in female adolescents.
Soyka LA; Grinspoon S; Levitsky LL; Herzog DB; Klibanski A
J Clin Endocrinol Metab; 1999 Dec; 84(12):4489-96. PubMed ID: 10599707
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance.
Cusi K; DeFronzo R
J Clin Endocrinol Metab; 2000 Sep; 85(9):3077-84. PubMed ID: 10999789
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations.
Clark RG
Horm Res; 2004; 62 Suppl 1():93-100. PubMed ID: 15761240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
